We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
June 10, 2022
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces June 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
June 8, 2022
Crinetics Presents Clinical and Research Results at ENDO 2022
Crinetics Pharmaceuticals to present findings from Phase 1 programs of CRN04894 and CRN04777 as well as discovery of PTHR1 antagonist at ENDO 2022.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:
- Acromegaly
- Neuroendocrine tumors (NETs)
- Carcinoid syndrome
- Congenital hyperinsulinism (congenital HI)
- Syndromic hyperinsulinism (syndromic HI)
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
Our once-daily, oral, investigational drug for the treatment of acromegaly is in Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|